Dutch biotech uniQure recently announced that its novel gene therapy, AMT-130 (ifezuntirgene inilparvovec), demonstrated ...

Australian biotech Neurizon Therapeutics (ASX: NUZ) said the US regulator has lifted the clinical hold on its lead drug ...

Skye Bioscience (Nasdaq: SKYE) reported topline data from a mid-stage trial showing that its obesity drug nimacimab failed to ...

Belgian biotech Bioxodes has appointed Philippe Monteyne as chairman of its board, replacing Pierre Detrixhe. The move comes ...

US lobby group Pharmaceutical Research and Manufacturers of America (PhRMA) revealed that member companies, thanks to ...

Oxford, UK-based clinical-stage biotech Theolytics today announced the appointment of Dr Matilde Saggese, as chief medical ...

The atrial fibrillation (AF) market across the eight major markets (8MM) is forecast to decline at a negative compound annual ...

AstraZeneca (LSE: AZN) has reported positive top-line results from its second Phase III trial of baxdrostat, showing the oral therapy cut blood pressure significantly in patients with ...

UK-based Trogenix, a biotech founded by VC firm 4BIO Capital developing innovative cancer therapies, has secured a £70 ...

South Korean biosimilars company Celltrion has presented real-world evidence (RWE) supporting the use of subcutaneous (SC) ...

Family-controlled Italian biopharma Chiesi Group and US genetic medicines company Arbor Biotechnologies have announced an ...

London-listed Hikma Pharmaceuticals and its long-standing partner South Korea’s Celltrion have signed exclusive licensing ...